Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Additionally we are shipping Sclerostin Kits (50) and Sclerostin Proteins (12) and many more products for this protein.
Showing 10 out of 92 products:
Human Polyclonal Sclerostin Primary Antibody for IHC (p), WB - ABIN390193
Semenov, He: LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. in The Journal of biological chemistry 2006
Show all 2 references for ABIN390193
Human Polyclonal Sclerostin Primary Antibody for EIA, IHC (p) - ABIN358751
Ellies, Viviano, McCarthy, Rey, Itasaki, Saunders, Krumlauf: Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006
Show all 2 references for ABIN358751
The aims of this study were to evaluate OCN and sclerostin levels in subjects who underwent coronary artery bypass graft (CABG) surgery compared with those in normal controls.
two affected siblings who carried a novel nonsense mutation of SOST in a consanguineous family from China, is reported.
Sclerostin serum levels are not associated with an adverse metabolic profile during pregnancy in women with GDM and PE
Quantitative RT-PCR analysis showed that SOST expression dose-dependently decreased with increasing Wnt (show WNT2 Antibodies) signaling, while BMP4 (show BMP4 Antibodies) induced SOST expression
SOST and DKK1 (show DKK1 Antibodies) have opposing effects on PC3 (show PCSK1 Antibodies) cell invasion and bone-derived Wnt (show WNT2 Antibodies) signaling positively contributes to the invasive phenotypes of PC3 (show PCSK1 Antibodies)
The correlation of SOST polymorphisms with changes of BMD (show BEST1 Antibodies) and bone biomarkers after treatment was analyzed.
highly sulfated (show SULF1 Antibodies) glycosaminoglycans might control bone homeostasis via interference with sclerostin/LRP5 (show LRP5 Antibodies)/6 complex formation.
Serum sclerostin was associated with serum intact parathyroid hormone (show PTH Antibodies) in patients undergoing peritoneal dialysis.
Sclerostin and DKK-1 (show DKK1 Antibodies) concentrations were markedly lower in HIV-infected youths
Serum sclerostin levels inversely associated with vascular calcification burden and progression in prevalent renal transplant recipients
Our results suggested that sclerostin could be expressed in the liver and sustained successfully at high levels in the blood by using the PhiC31 integrase system, leading to trabecular bone loss.
Sclerostin depletion enhances tibial fracture healing.
SOST gene is involved in the regulation of renal interstitial fibrosis (RIF) progression. In obstructive kidney injury, SOST gene deletion would probably enhance renal fibrogenic response and promote the progression of RIF.
Data (including data from studies in knockout/transgenic mice) suggest that Lrp6 (lipoprotein receptor-related protein 6 (show LRP6 Antibodies)) is required for suppression of Sost expression by parathyroid hormone (show PTH Antibodies) (here, human PTH (show PTH Antibodies) peptide 1-34).
These in vivo data support in vitro studies regarding the mechanism of HBM (show LRP5 Antibodies)-causing mutations, and imply that HBM LRP5 (show LRP5 Antibodies) receptors differ in their relative sensitivity to inhibition by SOST and DKK1 (show DKK1 Antibodies).
These findings indicated that AMPK (show PRKAA1 Antibodies) regulated RANKL (show TNFSF11 Antibodies) and sclerostin expression through the mevalonate pathway in osteocytes.
Sclerostin inhibits bone formation through Lrp5 (show LRP5 Antibodies) interaction.
thyroid hormone (show PTH Antibodies)-induced changes in bone remodeling are associated with a divergent regulation of DKK1 (show DKK1 Antibodies) and sclerostin
increased sclerostin production achieved by HDAC5 (show HDAC5 Antibodies) shRNA is abrogated by simultaneous knockdown of MEF2C (show MEF2C Antibodies), indicating that MEF2C (show MEF2C Antibodies) is a major target of HDAC5 (show HDAC5 Antibodies) in osteocytes
sclerostin is regulated by glutathione, N-acetylcysteine and lipoic acid in osteocytes in a process involving JNK (show MAPK8 Antibodies) and ERK1/2 (show MAPK1/3 Antibodies)
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.